All You Need to Know About Cardinal (CAH) Rating Upgrade to Buy
Cardinal (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should Value Investors Buy Cardinal Health (CAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health to Acquire Solaris Health for Urology Expansion
CAH is set to buy Solaris Health for $2.4B, boosting urology presence with 750+ providers and expanding Specialty Alliance reach.
After Plunging 9.1% in 4 Weeks, Here's Why the Trend Might Reverse for Cardinal (CAH)
The heavy selling pressure might have exhausted for Cardinal (CAH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Brokers Suggest Investing in Cardinal (CAH): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Compared to Estimates, Cardinal (CAH) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cardinal Health (CAH) Tops Q4 Earnings Estimates
Cardinal Health (CAH) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.84 per share a year ago.
Cardinal Health to Extend Reach by Acquiring Solaris Health
Cardinal Health's multi-specialty management services organization (MSO), The Specialty Alliance, plans to acquire urology MSO Solaris Health. Cardinal Health will enable the acquisition by providing about $1.9 billion in cash to The Specialty Alliance and will own about 75% of The Specialty Alliance after the acquisition of Solaris Health, Cardinal Health said in a Tuesday (Aug.
CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls
Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Cardinal Health, Inc. (CAH) Q4 2025 Earnings Call Transcript
Cardinal Health, Inc. (NYSE:CAH ) Q4 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Aaron E. Alt - Chief Financial Officer Jason M.
Cardinal Health Stock Tumbles on Earnings and $1.9 Billion Solaris Health Purchase
The company will acquire Solaris Health, a urology management services organization, for around $1.9 billion in cash.
Cardinal Health Q4 Preview: Accelerating Autoimmune, Urology And Oncology, Buy
Initiating Cardinal Health, Inc. with a Buy rating and $239 fair value, driven by specialty distribution growth and successful GMPD turnaround. Specialty segments in autoimmune, urology, and oncology are strategic growth drivers, outpacing traditional pharmaceutical markets and accelerating overall company growth. Recent urology acquisitions and strong specialty focus position Cardinal for above-market growth, despite near-term revenue headwinds from a customer contract expiration.
